Supervisory Board

Dr Karl Benedikt Biesinger is an attorney and partner at biesinger diener Rechtsanwaltsgesellschaft mbH in Heidelberg. He completed his law studies at the Eberhard Karls University of Tübingen and the Albert Ludwig University of Freiburg, Germany. He received his doctorate from the University of Tübingen, Germany. Dr Biesinger worked as a research assistant at the Max Planck Institute for Foreign and International Criminal Law in Freiburg and at the Chair of Civil and Commercial Law at the Eberhard Karls University of Tübingen. Dr Biesinger is Chairman of the Supervisory Board of SNP Schneider-Neureither & Partner SE (Data Transformation) and founder and managing director of Oorcca GmbH (ERP software).

Dr Georg F. Baur was re-elected to the Supervisory Board on 15 May 2025 and is its current Deputy Chairman. Dr Baur works as entrepreneur in the areas of private investments and asset management. Between 1990 and 1992, he was Managing Partner of Lehndorff Vermögensverwaltungs GmbH. From 1979 to 1989, Dr Baur held various positions at JP Morgan, ultimately as Managing Director and Treasurer of the bank in London. He holds a PhD from the University of St. Gallen, Switzerland.

Dr Mathias Hothum was re-elected by the Annual General Meeting on 15 May 2025. Dr Hothum serves as Managing Director of dievini Verwaltungs GmbH, which in turn acts as the manager of dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, a company that supports and mentors SAP founder Dietmar Hopp in his investments in life sciences and advises the companies from the industry in which Mr Hopp invests on their corporate and business development. Since 1992, Dr Mathias Hothum is owner and managing director of HMM Consulting in Walldorf. With his expertise and experience of twenty years as a self-employed consultant in the area of health care he advised not only companies. He also shared his expertise with students as a lecture at the SRH Hochschule Heidelberg. Dr Hothum received his diplom degree in Economics from the University of Mannheim. He went on to do his PhD at the University of Magdeburg.

Dr Klaus Schollmeier is a consultant for pharmaceutical and biotech companies. He holds a doctorate in biology from the University of Düsseldorf, Germany, and has been an Associate Professor of Research at Boston University Medical School, Massachusetts, USA, since 1991.

Dr Schollmeier looks back on many years of experience as a board member of various biotech and pharmaceutical companies, including SuppreMol, Munich, Germany, Santhera, Basel, Switzerland, and Graffinity Pharmaceuticals AG, Heidelberg, Germany. He previously held various positions at ING-BHF Bank, BASF, Knoll and Abbott. He is also Chairman of the Supervisory Board of Tacalyx AG and a member of the Supervisory Boards of Eternygen GmbH, CureVac, Novaliq, Anergis Pharma, Affiris Pharma and Modra Pharmaceuticals and act as business angel for start-up companies in Europe.

Dr Birgit Kudlek was re-elected as member of the Supervisory Board on 15 May 2025. Dr Kudlek has served as Chief Operating Officer and Chief Development Officer as well as Managing Director of AENOVA Holding GmbH in Starnberg. From 2009 to 2013, she was Head of the Sandoz Development Center Network at Sandoz International in Holzkirchen. From 2007 to 2008, she was an Executive Board Member of LTS Lohmann Therapie-Systeme, Andernach, where she was responsible for Technical Operations and Quality. From 2003 to 2007, Dr Kudlek worked for ratiopharm, Ulm, in various management positions within Technical Operations and Development, before taking over responsibility for global development activities. Prior to that Dr Kudlek was employed for more than four years as a consultant at Accenture, Kronberg. She started her career as Managing Assistant at Hoechst Marion Roussel, today Sanofi Aventis, Frankfurt. Birgit Kudlek studied Pharmaceutical Science as well as Economics and holds a PhD in Pharmaceutical Technology from the Technical University of Braunschweig.

Dr Liu was re-elected by the Annual General Meeting on 15 May 2025. Since 2020, Dr Liu is Chief Scientific Officer (CSO) at Huadong Medicine and President of Huadong Global Development in Hangzhou, China. Prior to that, he served as President R&D at Raynovent Biotechnology Co., Ltd, Guangzhou, China. From 2007 to 2019, he was Head of Clinical Development, Clinical Director and Medical Development Leader at GlaxoSmithKline (USA). Dr Liu also worked at Wyeth (USA, now Pfizer, 1998-2003) and Forest Labs (USA, now Allergan, 2003-2007) with increasing responsibilities. His more than 20 years of industry experience include clinical and preclinical research & development of medicinal products. He contributed to several globally launched products. He obtained a PhD in Immunology/Biochemistry from Nankai University, Tianjin, China, a Master of Science in computer sciences from New York Long Island University, New York, USA, and a Bachelor of Science in Chemistry, Nankai University.

Dr Xia was re-elected as member of the Supervisory Board by the Annual General Meeting on 15 May 2025. He has been the Director of ADC Research Center at Huadong Medicine in Hangzhou, China since 2022. He leads the early research and development of the ADC pipeline and develops Huadong Medicine's R&D strategy. Previously, Dr Xia served as senior researcher. In this position, he led the preclinical biology team and conducted several projects, including a collaborative drug discovery project for innovative cancer therapeutics using AI and a preclinical co-discovery and development project. In addition, Dr. Xia has been responsible for due diligence processes for in-licensing or strategic acquisitions, R&D strategies, and pipeline strategies. Dr. Xia holds a Ph.D. in chemical and physical biology from Vanderbilt University, Nashville, Tennessee, USA, and a B.Sc. in biological sciences from Nanyang Technological University, Singapore.